Patents Assigned to FRED
  • BIO-SPECIMEN REFRIGERATION SYSTEM
    Publication number: 20220161263
    Abstract: Devices and methods for bio-specimen refrigeration are provided. In an embodiment, the bio-specimen refrigeration devices of the present disclosure include a housing having a lid and a base portion, wherein the lid is selectively moveable between an open position and a closed position; a coolant cartridge chamber disposed in the housing and configured to fluidically couple with a coolant cartridge disposed in the coolant cartridge chamber; and a cooling chamber disposed in the housing and configured to receive a fluid coolant from the coolant cartridge, wherein in the closed position, the lid seals the cooling chamber.
    Type: Application
    Filed: November 19, 2021
    Publication date: May 26, 2022
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Amanda G. Paulovich, Richard Ivey, Jacob Kennedy, Travis Lorentzen, Amanda Woodcock, Scott C. Thielman, Elijah E. Hooper
  • PROTEIN RESIDUE MAPPING USING A COMBINATION OF DEEP MUTATIONAL SCANNING AND PHAGE DISPLAY HIGH THROUGHPUT SEQUENCING
    Publication number: 20220154170
    Abstract: The current disclosure provides protein residue mapping using a combination of deep mutational scanning and phage display high throughput sequencing. The disclosed methods allow mapping of antibody epitopes and determination of changes in residues of a protein that abolish binding of the protein to a candidate binding molecule.
    Type: Application
    Filed: February 28, 2020
    Publication date: May 19, 2022
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Julie Overbaugh, Meghan Garrett
  • HYDROGEL COMPOSITIONS AND METHODS FOR TREATEMENT OF MALIGNANCIES
    Publication number: 20220143210
    Abstract: Methods and compositions for treatment of malignancies are provided. The methods utilize implantation of engineered, programmable hydrogel depots capable of long-term molecule release into close proximity of the tumor. By providing gradients of immune cell chemokines and releasing immune checkpoint inhibitors, the hydrogel implants are effective at elimination of tumor cells via immune cell-mediated cell death.
    Type: Application
    Filed: February 27, 2020
    Publication date: May 12, 2022
    Applicants: Fred Hutchinson Cancer Research Center, University of Washington
    Inventors: James Olson, Eric Nealy, Cole DeForest, Kenneth Brasel
  • IDENTIFICATION AND TREATMENT OF T-CELL EPITOPES OF SHORT H2A ONCOHISTONES
    Publication number: 20220133760
    Abstract: The present disclosure describes methods of treating lymphoma that expresses a short histone H2A variant. In some embodiments, the method can comprise collecting a sample from a subject having or suspected of having lymphoma, detecting a short histone H2A variant (sH2A) expression level in the sample collected from the subject, and administering to the subject a therapeutically effective dose of an anthracycline agent, if the subject has sH2A variant expression level that is detectable. In other embodiments, the sH2A is the H2A.B variant. In other embodiments, the anthracycline agent can be aclarubicin.
    Type: Application
    Filed: November 1, 2021
    Publication date: May 5, 2022
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Jay Francis Sarthy, Antoine Molaro, Marie Bleakley, Guo-Liang Chew
  • CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR
    Publication number: 20220125814
    Abstract: Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor in combination with a nicotinamide adenine dinucleotide (NAD) salvage pathway precursor are described. Cancers treated with the combination therapies can be nicotinamide riboside kinase (NMRK1) low cancers and/or Myc high cancers and can include various forms of glioblastomas.
    Type: Application
    Filed: March 20, 2020
    Publication date: April 28, 2022
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: David Hockenbery, Patrick Paddison
  • Methods of using IL-21 for adoptive immunotherapy and identification of tumor antigens
    Patent number: 11306289
    Abstract: Methods for preparing ex vivo T cell cultures using IL-21 compositions for use in adoptive immunotherapy are described. Addition of IL-21 to cultures of non-terminally differentiated T cells population, either isolated or present in peripheral blood mononuclear cells are exposed to one or more tumor antigens, and in the presence of IL-21 compositions and antigen presenting cells (APCs), the resulting T cell population has an enhanced antigen-specificity, and can be reintroduced into the patient. Methods are also disclosed for identifying tumor antigens by culturing T cell populations exposed to IL-21 compositions and APCs in the presence of tumor material.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: April 19, 2022
    Assignee: Fred Hutchinson Cancer Research Center
    Inventor: Cassian Yee
  • SPATIAL MAPPING OF CELLS AND CELL TYPES IN COMPLEX TISSUES
    Publication number: 20220106623
    Abstract: Systems and methods to tag cells in a tissue sample with spatial identifiers, so that spatial reconstruction of cell locations within a tissue can be achieved after tissue disaggregation are described. The systems and methods allow the control or directing of specific spatial identifiers spatially within or throughout a tissue to individual cells or to a small population of cells so that cell position can be determined by computational deconvolution of the spatial identifiers after tissue disaggregation. The systems and methods can be combined with single cell expression analysis to correlate cell types with cell location within a structure, such as a tumor.
    Type: Application
    Filed: November 21, 2019
    Publication date: April 7, 2022
    Applicant: Fred Hutchinson Cancer Research Center
    Inventor: Jason Bielas
  • REDUCING CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
    Publication number: 20220098613
    Abstract: Systems and methods to selectively protect therapeutic cells by reducing CD33 expression in the therapeutic cells and targeting non-therapeutic cells with an anti-CD33 therapy. The selective protection results in the enrichment of the therapeutic cells while simultaneously targeting any diseased, malignant and/or non-therapeutic CD33 expressing cells within a subject.
    Type: Application
    Filed: September 12, 2019
    Publication date: March 31, 2022
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Hans-Peter Kiem, Olivier Humbert, Roland B. Walter
  • Faecal detection sensor
    Patent number: 11280757
    Abstract: The invention provides the present invention provides a faecal detection sensor for an absorbent article. The sensor includes a faeces-sensitive material that reacts to the presence of a constituent of faecal matter, wherein the sensor exhibits an electrical property that changes following the reaction of the faeces-sensitive material. In embodiments of the invention the faeces sensitive material is a material that reacts due to the presence of a sulfur-containing compound in faecal matter, such as metallic faeces-sensitive materials, or is a material that reacts with a faecal enzyme and/or other constituents of faecal matter, such as organic faeces-sensitive materials.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: March 22, 2022
    Assignee: FRED BERGMAN HEALTHCARE PTY LTD
    Inventors: Peter Curran, Mehdi Azimi, Hadi Mashin-Chi, Peter Aigner, Juuso Olkkonen, Anna-Marja Aura, Anu Vaari, Antti Nyyssola, Lisa Hakola, Maria Smolander
  • ENHANCED GENERATION OF CYTOTOXIC T-LYMPHOCYTES BY IL-21 MEDIATED FOXP3 SUPPRESSION
    Publication number: 20220073879
    Abstract: A method of carrying out adoptive immunotherapy by administering a subject an antigen-specific cytotoxic T lymphocytes (CTL) preparation in a treatment-effective amount is described. In the method, the CTL preparation is preferably administered as a preparation of an in vitro antigen-stimulated and expanded primate CTL population, the CTL population: (i) depleted of FoxP3+T lymphocytes prior to antigen stimulation; (ii) antigen-stimulated in vitro in the presence of interleukin-21; or (iii) both depleted of FoxP3+T lymphocytes prior to antigen stimulation and then antigen-stimulated in vitro in the presence of interleukin-21. Methods of preparing such compositions, and compositions useful for carrying out the adoptive immunotherapy, are also described.
    Type: Application
    Filed: August 11, 2021
    Publication date: March 10, 2022
    Applicant: The Fred Hutchinson Cancer Research Center
    Inventors: Cassian YEE, Yongqing LI
  • Bi-specific molecule for cell-specific Notch inhibition and related methods and compositions
    Patent number: 11261250
    Abstract: This disclosure provides compositions and related methods providing targeted cell-specific inhibition of Notch receptor signaling. The disclosure provides a bi-specific molecule with separate domains that target the intended cell-type and the Notch receptor on that cell-type. The disclosure also provides for nucleic acids, vectors, and cells allowing for the expression of the bi-specific fusion molecules. The disclosure also provides related methods of making and using the bi-specific fusion molecule to inhibit Notch signaling in target cells of interest, including for the treatment of diseases characterized by a dysregulation of Notch signaling.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: March 1, 2022
    Assignees: FRED HUTCHINSON CANCER RESEARCH CENTER, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Irwin Bernstein, Vincent Luca, Kenan Christopher Garcia
  • Chelating platform for delivery of radionuclides
    Patent number: 11235076
    Abstract: Siderocalin-metal chelator combinations that bind metallic radioisotopes used in nuclear medicine with high affinity are described. The high affinity siderocalin-metal chelator combinations include a number of chelator backbone arrangements with functional groups that coordinate with metals. The siderocalin-metal chelator combinations can be used to deliver radionuclides for imaging and therapeutic purposes.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: February 1, 2022
    Assignees: Fred Hutchinson Cancer Research Center, The Regents of the Universitv of California
    Inventors: Roland K. Strong, Peter Rupert, Rebecca J. Abergel, Ilya Captain, Gauthier J P Deblonde
  • REDUCED AND MINIMAL MANIPULATION MANUFACTURING OF GENETICALLY-MODIFIED CELLS
    Publication number: 20220025403
    Abstract: Nanoparticles to genetically modify selected cell types within a biological sample that has been subjected to reduced or minimal manipulation are described. The nanoparticles deliver all components required for precise genome engineering and overcome numerous drawbacks associated with current clinical practices to genetically engineer cells for therapeutic purposes.
    Type: Application
    Filed: December 5, 2019
    Publication date: January 27, 2022
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Jennifer E. Adair, Reza Shahbazi
  • Method of measuring adaptive immunity
    Patent number: 11214793
    Abstract: A method of measuring immunocompetence is described. This method provides a means for assessing the effects of diseases or conditions that compromise the immune system and of therapies aimed to reconstitute it. This method is based on quantifying T-cell diversity by calculating the number of diverse T-cell receptor (TCR) beta chain variable regions from blood cells.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: January 4, 2022
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Harlan S. Robins, Edus H. Warren, III, Christopher Scott Carlson
  • CONSTRUCTION OF A TINY HOUSE ON WHEELS
    Publication number: 20210388603
    Abstract: A mobile building constructed on a trailer, comprising: a wheeled trailer upon which the building is built, a floor and a plurality of walls secured to the trailer; and a roof structure, wherein external sides of the walls are braced with sheeting secured to the walls, the sheeting extending from a base of the building and securing to the roof structure.
    Type: Application
    Filed: October 16, 2019
    Publication date: December 16, 2021
    Applicant: Fred's Tiny Houses Pty Ltd
    Inventor: Fred SCHULTZ
  • CIRCULAR TANDEM REPEAT PROTEINS
    Publication number: 20210388119
    Abstract: Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.
    Type: Application
    Filed: June 28, 2021
    Publication date: December 16, 2021
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Philip Bradley, Barry L. Stoddard
  • CELL-STORED BARCODED DEEP MUTATIONAL SCANNING LIBRARIES AND USES OF THE SAME
    Publication number: 20210363661
    Abstract: Cell-stored barcoded viral protein deep mutational scanning libraries are described. The libraries can be used to map resistance mutations to therapeutic treatments. The libraries can be used to predict viruses that become resistant to therapeutic compounds and/or may more easily evolve to infect new species. The libraries can also be used to more safely study dangerous viruses that normally require high safety biocontainment facilities. The libraries include features that allow efficient collection and assessment of informative data, obviating many bottlenecks of previous approaches.
    Type: Application
    Filed: June 28, 2019
    Publication date: November 25, 2021
    Applicants: Fred Hutchinson Cancer Research Center, University of Washington
    Inventors: Jesse Bloom, Adam S. Dingens, Katharine Dusenbury, Caelan Radford
  • PHARMACOPROTEOMICS PLATFORM IDENTIFYING KINOME FEATURES REGULATING DRUG RESPONSE IN CANCER
    Publication number: 20210348171
    Abstract: The disclosure provides methods and compositions for increasing sensitivity, or decreasing resistance, of cancer cells to chemotherapeutic agents such as kinase inhibitor agents. In some embodiments, the cancer cells are hepatocellular carcinoma (HCC) cells. The methods and compositions can be integrated into methods of treatment of a subject with cancer, which can further comprise administering a chemotherapeutic agent such as kinase inhibitor agents. In another aspect, the disclosure provides a method for profiling the kinome of a cell or group of similar cells that incorporates kinase capture reagents and mass spectrometry analysis.
    Type: Application
    Filed: May 6, 2021
    Publication date: November 11, 2021
    Applicants: University of Washington, Fred Hutchinson Cancer Research Center
    Inventors: Shao-En Ong, Martin Golkowski, Ho-Tak Lau, Taranjit S. Gujral
  • NEWBORN SCREENING FOR PRIMARY IMMUNODEFICIENCIES, CYSTINOSIS, AND WILSON DISEASE
    Publication number: 20210341492
    Abstract: Newborn screening for primary immunodeficiencies, cystinosis, and Wilson disease is described. The newborn screening can detect these disorders from dried blood spots already routinely collected at the time of birth. Early detection of these disorders will greatly improve patient outcome as each of them can be fatal once symptoms emerge.
    Type: Application
    Filed: October 4, 2019
    Publication date: November 4, 2021
    Applicants: Seattle Children's Hospital d/b/a Seattle Children's Research Institute, Fred Hutchinson Cancer Research Center
    Inventors: Sihoun Hahn, Sunhee Jung, Jeffrey Whiteaker, Troy Torgerson, Amanda Paulovich, Christopher Collins, Remwilyn Dayuha
  • SEQUENTIAL IMMUNIZATION STRATEGIES TO GUIDE THE MATURATION OF ANTIBODIES AGAINST HUMAN IMMMUNODEFICIENCY VIRUS
    Publication number: 20210308256
    Abstract: Sequential immunization strategies to guide the maturation of antibodies against the human immunodeficiency virus (HIV) are described. The sequential immunization strategies utilize an HIV envelope protein (Env) that binds germline (gl) B cells as a first (prime) immunization and an Env with a functional glycosylated N276 as a second (boost) immunization. The sequential immunization strategies successfully elicit neutralizing antibodies against HIV.
    Type: Application
    Filed: August 29, 2019
    Publication date: October 7, 2021
    Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Leonidas Stamatatos, Andrew McGuire, Katherine Rachael Parks